HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carlotti, E. Articles by Rambaldi, A. Search for Related Content PubMed PubMed Citation Articles by Carlotti, E. Articles by Rambaldi, A.

FcRIIIA and FcRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab

From the Divisione di Ematologia, Ospedali Riuniti Bergamo (EC, EO, SS, AR, JG, AR); CRUK Medical Oncology Laboratory, Barts and the London, Queen Mary School of Medicine and Dentistry, London, United Kingdom (EC); Dipartimento di Ematologia, Scienze Biomediche, Universita’, Catania (GAP, DT); Dipartimento di Biotecnologie Cellulari ed Ematologia, Università ‘La Sapienza’, Rome, Italy (AP, RF)

Correspondence: Alessandro Rambaldi, M.D., USC Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy. E-mail: arambaldi{at}ospedaliriuniti.bergamo.it

We analyzed FcRIIIA-158V/F and FcRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between FcRIIIA-158VV/VF and FcRIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH⁺ cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.

Key words: FcR polymorphisms, follicular lymphoma, BCL2/IgH rearrangements.

This article has been cited by other articles:

				M. Leidi, E. Gotti, L. Bologna, E. Miranda, M. Rimoldi, A. Sica, M. Roncalli, G. A. Palumbo, M. Introna, and J. Golay M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro J. Immunol., April 1, 2009; 182(7): 4415 - 4422. [Abstract] [Full Text] [PDF]

				N. M. Pennell, T. Bhanji, L. Zhang, A. Seth, C. A. Sawka, and N. L. Berinstein Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma Haematologica, August 1, 2008; 93(8): 1265 - 1267. [Full Text] [PDF]